Press Release | Association for Accessible Medicines

Sep 25, 2024 | AAM

John Murphy Named President and CEO of AAM

congress building

Sep 24, 2024 | Comms Temp

AAM Urges Congress to Pass Key Bills Considered by the Senate HELP Committee This Week

Hatch-Waxman Turns 40

Sep 24, 2024 | AAM

40 Years of Hatch-Waxman – Trillions in Savings for Patients

Scientists in lab

Sep 18, 2024 | AAM

Generic Medicines Increase Patient Access More Than Government Negotiated Price Controls

Sep 13, 2024 | AAM

Statement Regarding Senate Judiciary Committee Markup of the PREVAIL Act and the PERA Act

Sep 10, 2024 | AAM

AAM and the Biosimilar Council Host Patent Abuse Congressional Briefing: What’s Truly Preventing Low-Cost Medicines from Getting to Patients: A Look at the Broken Patent System

2024 U.S. Generic and Biosimilar Medicines Savings Report

Sep 5, 2024 | AAM

Generic and Biosimilar Medicines Save $445 Billion in 2023

Closeup cashless wireless payment with credit card at the pharmacy

Aug 15, 2024 | Ashley Henyan

Benefit Projected by CMS Price Setting Cannot Compare to Benefit of Generic and Biosimilar Medicines

Jul 9, 2024 | Brian Hart

FTC Report Critical of PBMs Highlights Middlemen Profits Over Patient Savings

Jun 26, 2024 | Ashley Henyan

Blog: Bill Addressing Drug Shortages Provides Long Overdue Relief from Penalties Hurting Generic Drug Market

May 30, 2024 | Brian Hart

AAM Submits Comments to HHS and FTC on the Impact of GPOs and Wholesalers on Access to Generic Medicines

May 21, 2024 | Brian Hart

AAM Applauds Senate Judiciary Committee Efforts to Protect Patients and Skinny Labeling